Replies to post #250036 on Biotech Values

[DewDiligence]

PFE provides 2024 guidance including SGEN:

https://s28.q4cdn.com/781576035/files/doc_downloads/2023/12/Pfizer-Provides-Full-Year-2024-Guidance-FINAL-12-13-23.pdf

▪ Full-Year 2024 Revenue Guidance Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition

- Anticipates Approximately $8 Billion in Revenues for Comirnaty and Paxlovid

- Seagen Expected to Contribute Approximately $3.1 Billion of Revenues

▪ Expects Full-Year 2024 Operational [i.e. constant currency] Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty and Paxlovid Revenues, and 3%-5% Excluding Both Seagen Contribution and Comirnaty and Paxlovid Revenues

▪ 2024 Adjusted Diluted [i.e. non-GAAP] EPS Guidance Range of $2.05 to $2.25 Includes Expected Impact of Seagen Acquisition

▪ Enterprise-Wide Cost Realignment Program Now Expected to Deliver Annual Net Cost Savings of at Least $4.0 Billion, an Incremental $500 Million Versus Mid-Point of Guidance Range Provided on August 1, 2023

CC slides:
https://s28.q4cdn.com/781576035/files/doc_downloads/2023/12/2024-Financial-Guidance-Presentation_Dec-13-2023_vF.pdf

[DewDiligence]

PFE’s CEO today on SGEN: “We are not acquiring the golden eggs… we are acquiring the goose!”